Antibody-based therapy in Alzheimer's disease

Areas covered: The rationale and putative mode of action of antibody-based immunotherapy in AD and delineates correlations for other neurodegenerative diseases. Current clinical trials and recent results of therapeutic antibodies in AD are presented. Expert opinion: Antibodies against A beta beta will not only broaden the therapeutic repertoire but also our knowledge about the pathology in AD. Further results of the clinical trials and new antibody-based approaches will shed light on the importance of A beta beta and its removal in AD.